Business Wire

American Express Expands Growing Global Lounge Collection with the Opening of The CENTURION® Lounge in Hong Kong and Philadelphia

Del

American Express (NYSE:AXP) today announced the expansion of its signature airport lounge network, The Centurion Lounge, with two new locations in Hong Kong and Philadelphia International Airports. Hong Kong, which opens on October 2nd, marks the first Centurion lounge in Asia, and Philadelphia, opening in late October, marks the 8th U.S. location of this growing network of premium airport retreats.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170929005134/en/

The Centurion Lounge at Hong Kong International Airport - Entry (Photo: Business Wire)

The Centurion Lounge at Hong Kong International Airport - Entry (Photo: Business Wire)

“We are excited to introduce our first Centurion Lounge in Hong Kong, which continues to be a top destination for our Card Members and an epicenter for contemporary culture,” said Janey Whiteside, executive vice president and general manager of Global Charge Products, Benefits & Services, American Express. “We’re equally thrilled to expand our offerings in the U.S. with the opening of a Centurion Lounge location in the growing travel hub of Philadelphia. These two new additions to our Centurion Lounge offerings and broader Global Lounge Collection build on our ongoing commitment to provide our increasingly global Card Members with access to premium travel benefits and experiences.”

The Centurion Lounge is the signature lounge program within the broader American Express Global Lounge CollectionSM, which provides Platinum Card® and Centurion Members with access to the most lounges across the globe compared to other U.S. credit cards, including access to more than 1,100 lounges around the world, in 500 plus cities, across 120 countries and counting.

The Centurion Lounge at Hong Kong International Airport

Opening on October 2nd, The Centurion Lounge in Hong Kong International Airport is located in Terminal 1. Covering approximately 8,000 square feet, the lounge offers an expansive escape for Card Members to relax, refresh and reboot. The space features a unique selection of premium amenities, food and beverages inspired by the local culture.

Amenities include:

  • A premium buffet featuring both locally and internationally inspired dishes.
    • Example menu items include French toast with maple syrup and mixed berry compote, assorted Dim Sum baskets, stir-fried rice with eggs, mushrooms and vegetables, chicken congee, gnocchi with Pomodoro sauce, pan fried sole fillet with caper cream sauce, and vanilla mango panna cotta.
  • A complimentary full bar with custom cocktails created by renowned mixologist Jim Meehan and wine selections handpicked by renowned wine authority Anthony Giglio*
  • Private phone areas and a meeting room, plus a workspace outfitted with a computer bar
  • Restrooms and a private shower suite outfitted with L’Occitane amenities
  • A private area exclusively available for Centurion Members and their guests, which will offer access to a dedicated Member Services Professional to help with any specific travel, reservation or card services requests
  • The private Centurion area will also feature an a la carte menu designed by Michelin star chef, Lau Yiu Fai of Yan Toh Heen at the InterContinental Hong Kong.
    • Chef Lau’s menu will offer Cantonese dishes such as baked pork in puff pastry, crispy spring rolls with kimchi and pork, crispy fresh prawns with black truffles, braised wagyu beef cheek and turnip, barbecued pork with honey and steamed rice, and baked egg tartlettes with bird’s nest, among others.

The Centurion Lounge at Philadelphia International Airport

In the coming weeks, American Express will open a new 6,300 square foot Centurion Lounge located in Terminal A West of Philadelphia International Airport. In this new lounge Card Members can enjoy amenities including:

  • An Israeli-inspired food menu designed by four-time James Beard Award winning Israeli Cuisine Pioneer, Chef Michael Solomonov
  • A complimentary full bar with custom cocktails created by renowned mixologist Jim Meehan and wine selections handpicked by renowned wine authority Anthony Giglio*
  • Floor-to-ceiling windows with expansive internal and external views
  • Essentials for business and leisure travelers alike, including dedicated workspaces, power outlets, private phone areas, comfortable seating and access to high-speed Wi-Fi

American Express is excited to partner with Chef Michael Solomonov, the executive chef and co-owner of Philadelphia’s pioneering Israeli restaurant Zahav, to bring some of his favorite flavors to The Centurion Lounge in Philadelphia. Some of the items on Solomonov’s lounge menu include challah French toast with tehina and blackberries, Israeli salad with feta, kale tabbouleh with apples and pomegranate, Bulgarian kebabs with red pepper and white bean salad, and malabi with coconut and passionfruit.

"We are extremely honored to be a part of the American Express Centurion Lounge family and excited to help make their newest lounge an oasis of hospitality for Philadelphia travelers,” said Chef Michael Solomonov. “It's such an exciting time to be a Philadelphian, and I am grateful for the opportunity to show visitors to our historic town what the City of Brotherly Love is all about."

The two new lounges in Hong Kong and Philadelphia are the latest openings in American Express’ network of Centurion Lounges, which also includes locations at New York’s LaGuardia Airport, Las Vegas’ McCarran International Airport, Dallas/Fort Worth International Airport, San Francisco International Airport, Miami International Airport, Seattle-Tacoma International Airport and Houston’s George Bush International Airport.

In addition to the new locations, The Centurion Lounge at the Dallas/Fort Worth International Airport will be relocating to a larger space in Terminal D, opening in the first half of 2018. The new space will be approximately 3,000 square feet larger than the original space and will include additional amenities such as telephone rooms, a private mother’s room and an additional shower suite.

Access to The Centurion Lounge is complimentary and exclusive for Platinum Card and Centurion Members. Platinum Card Members may enter with up to two travel companions at no additional charge. Centurion Members may enter with their immediate family or up to two travel companions. Platinum Card or Centurion Members may purchase a one-day pass to The Centurion Lounge for additional guests for $50.**

Access to The Centurion Lounge and the broader Global Lounge Collection is among an expansive suite of benefits designed to create a more seamless travel experience for Platinum Card and Centurion Members. The Global Lounge Collection includes access to American Express Centurion Lounges, international American Express lounges, Delta Sky Club® for Card Members flying on Delta, Priority PassTM Select Lounges upon enrollment, Airspace Lounges and MAG U.S. Escape Lounges. Card Members can find a lounge at the Global Lounge Collection website or by using the Amex Mobile app.

Visit http://americanexpress.com/platinum for more about the Platinum Card.

About American Express

American Express is a global services company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpressinstagram.com/americanexpresslinkedin.com/company/american-expresstwitter.com/americanexpress, and youtube.com/americanexpress.

Key links to products, services and corporate responsibility information: charge and credit cardsbusiness credit cardsPlenti rewards programtravel servicesgift cardsprepaid cardsmerchant servicesAccertifycorporate cardbusiness travel, and corporate responsibility.

* Must be 21 years of age or older to consume alcohol. Please drink responsibly.

**Subject to availability/capacity.

Contact information

Heather Norton
Heather.A.Norton@aexp.com
212-640-0496
or
Margot Leeds
Margot.leeds@pmkbnc.com
212-373-0106

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19Pressemelding

Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom